Egalet's painkillers on the FDA fast track; Vitae bags $14M from Boehringer;

@FierceBiotech: Investigators: Personalized T cell attack spurs complete remissions of leukemia. Article | Follow @FierceBiotech

@JohnCFierce: Can a patient's dad succeed at Duchenne muscular dystrophy after all the biotech failures? Story | Follow @JohnCFierce

@DamianFierce: Raptor's Huntington's drug slowed the disease in a subset of patients, and that was enough to elate investors. News | Follow @DamianFierce

@EmilyMFierce: Gene therapy shows promise for treating heart attack victims. More from Scientific American | Follow @EmilyMFierce

> Recent IPO success story Egalet ($EGLT) secured FDA fast-track designations for Egalet-001 and Egalet-002, its abuse-deterrent pain medications. News

> Vitae Pharmaceuticals banked a $14 million milestone payment from partner Boehringer Ingelheim, tied to the start of a Phase I trial on the pair's BACE-blocking Alzheimer's disease candidate. More

> Oncothyreon ($ONTY) and Array BioPharma ($ARRY) have initiated a Phase Ib study of their HER2 inhibitor, ONT-380, in combination with Roche's ($RHHBY) Kadcyla in breast cancer patients. Item

> New York's Weill Cornell Medical College has kicked off a program designed to help its researchers better attract partners in the biopharma business. Release

Medical Device News

@FierceMedDev: S&N isn't the only one pursuing M&A to boost its sports medicine device offerings. Stryker is doing same. More | Follow @FierceMedDev

@MarkHFierce: Medtronic said its tiny wireless pacer has been implanted in its first U.S. patient. Release | Follow @MarkHFierce

@MichaelGFierce: BioMérieux's BioFire sets course for GI panel FDA clearance. Article | Follow @MichaelGFierce

> Syneron's revenue dips in Q4, but an aesthetic laser M&A deal gives a boost. Story

> A French outfit focused on medical imaging components is making inroads in China. Item

Pharma News

@FiercePharma: Best-read on the site yesterday, back for Day 2: Actavis inks $25B deal for Forest in bid to build its brand stable. More | Follow @FiercePharma

@TracyStaton: BioMarin's $380K price tag on Vimizim is high, but far from the highest. More | Follow @TracyStaton

@EricPFierce: New York AG says Teva, Ranbaxy were on a collusion course with pay-to-delay deals. Yesterday's story | Follow @EricPFierce

@CarlyHFierce: Tops on FiercePharmaMarketing yesterday: Eisai's revved-up Belviq marketing starting to pay off, analysts say. Story | Follow @CarlyHFierce

> Reuters: Bayer, Novartis, Reckitt eye $10B-$12B bids for Merck consumer unit. Report

> UCB taps biopharma chief to step up to CEO job, prep for new launches. News

> Roche may open Avastin data to sort out conflicting brain-cancer studies. More

> GlaxoSmithKline lobbies for restrictions on e-cigs, which compete with its nicotine products. Story

Pharma Manufacturing News

> 13 drugmakers picked for FDA's special import perks. Story

> Cold-chain costs were halved in African vaccine campaign. Article

> Excipient makers jump on audits as new regs kick in. News

> GSK plant goes more than three years without plant injury. More

> West Pharmaceutical benefits from emerging market growth. Piece

> India pressures Merck and GSK on vaccine prices. Item

Vaccines News

> Dynavax's hep B vaccine plans derailed by European request for extra safety data. Report

> Novartis' Bexsero sparks debate about transatlantic vaccine approvals. Article

> WHO reports success in distributing vaccines at ambient temperatures. More

> CDC researchers say measles outbreaks cost U.S. health authorities up to $5M in 2011. News

> Chinese researchers see pandemic potential in bird flu virus reassortment. Story

> India is pushing GSK and Merck to slash the cost of HPV vaccines. Item

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.